摘要
目的探索真实世界中参芎葡萄糖注射液治疗脊柱疾病的临床联合用药情况,为合理用药和进一步研究提供参考和思路。方法提取全国19家三甲医院信息系统中使用参芎葡萄糖注射液治疗脊柱疾病患者的医疗信息,标准化后,采用Apriori算法建立模型,使用Clementine12.0对联合用药信息进行关联分析。结果纳入551例脊柱疾病患者联合用药中,最常与参芎葡萄糖注射液联合使用的中药是鹿瓜多肽、脉络舒通颗粒、仙灵骨葆胶囊;西药是前列地尔、地塞米松、阿托品、苯巴比妥、泮托拉唑;中药类别是活血化瘀剂、补益剂、祛风除湿剂;西药类别是肾上腺皮质激素、抗生素、质子泵抑制剂、镇静催眠药、抗胆碱类药物等。结论参芎葡萄糖注射液治疗脊柱疾病联合用药广泛,西药间联合应用最常见,中西药联合应用频率次之,中药间联合频率最低。总体联合用药规律符合中西医对脊柱疾病病因机制的认识及基本治疗原则。
Objective To explore the co-medication with shenqiong glucose injection for spondylopathy in the real world so as to provide the references to the rational medication and further study.Methods The medical information of the patients with vertebral diseases prescribed shenqiong glucose injection were extracted from the medical system of 19 3A-class hospitals in China.After normalization,using Apriori alogorithm,the model was established.Using clementine 12.0,the association analysis was performed for the information of co-medication.Results Among the co-medications in 551 cases of spondylopathy,the Chinese herbal medicines mostly combined with shenqiong glucose injection were cervus and cucumis polypeptide,mailuo shutong granules and xianling gubao capsules.The western medicines were alprostadil,dexamethasone,atropine,Phenobarbital and pantoprazole.The Chinese herbal medicines were in the categories of the preparations for activating blood circulation and resolving blood,tonic drugs and the preparations for eliminating wind and damp.The western medicines were in the categories of adrenocortical hormone,antibiotics,proton pump inhibitors,sedative hypnotics and anticholinergic drugs.Conclusion Shenqiong glucose injection is widely used together with other drugs in the treatment of spondylopathy.The co-medication among western medicines is the most common.The co-medication frequency between Chinese medicine and western medicine is on the second top and the co-medication among Chinese medicines is the lowest.The overall rule of co-medication is coincident with the recognition of etiology and pathogenesis of spondylopathy and the basic treating principle.
作者
陈冠敏
谢雁鸣
刘峘
张寅
贾萍萍
庄严
CHEN Guan-min;XIE Yan-ming;LIU Huan;ZHANG Yin;JIA Ping-ping;ZHUANG Yan(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700;Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100700;Statistical Institute,Renmin University of China,Beijing 100872;The PLA Navy General Hospital,Beijing 100048)
出处
《世界中西医结合杂志》
2019年第2期176-181,共6页
World Journal of Integrated Traditional and Western Medicine
基金
国家“重大新药创制”科技重大专项(2015ZX09501004-001-002)
国家中医药管理局中医药行业科研专项(201507003)
北京市中医药科研发展专项(JJ2014-53)
中国中医科学院中医药“一带一路”合作专项(ZZ-10-018-03).
